De-escalated PTCy and ruxolitinib for GvHD prophylaxis in older patients undergoing alloSCT

PTCy based GvHD prophylaxis in myelofibrosisПодробнее

Ruxolitinib for Steroid-Refractory Acute GVHDПодробнее

Is it possible to efficiently prevent GvHD with a modified PTCy dosing schedule?Подробнее

Cyclophosphamide vs ATG for GvHD prevention in haplo-HSCT for adult ALLПодробнее

Outcomes of alloSCT with PTCy-based GvHD prophylaxis in elderly patients with acute leukemia and MDSПодробнее

Advances in GvHD management and prophylaxisПодробнее

Current approaches to GvHD prophylaxis and treatmentПодробнее

When would you use ATG vs PTCy for GvHD prophylaxis?Подробнее

Clinical Perspective: Integrating Ruxolitinib into the Treatment of Acute GVHDПодробнее

GVHD Outcomes With Post-Transplant Cyclophosphamide, Tacrolimus, and... in Stem Cell TransplantПодробнее

Can adding ATG to PTCy further reduce the risk of GvHD?Подробнее

Recent advances in the management of acute GvHDПодробнее

Dr David Snyder on When to Add Ruxolitinib to Treat GVHDПодробнее

Vedolizumab for GI acute GvHD prophylaxis after allogeneic transplantationПодробнее

Ruxolitinib and ibrutinib: the future for GvHD treatment?Подробнее

Approval of Ruxolitinib: Steroid-Refractory Acute GVHDПодробнее

REACH2: What patients with steroid-refractory acute GvHD respond best to ruxolitinib?Подробнее

Implications for Treating Acute GVHD With RuxolitinibПодробнее

Ruxolitinib: Treatment of Steroid-Refractory Acute GVHDПодробнее